This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders
Journal of Inherited Metabolic Disease Open Access 09 March 2018
-
Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study
Translational Psychiatry Open Access 29 August 2017
-
Emulsified omega-3 fatty-acids modulate the symptoms of depressive disorder in children and adolescents: a pilot study
Child and Adolescent Psychiatry and Mental Health Open Access 05 July 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bloch MH, Hannestad J . Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2011; e-pub ahead of print 20 September 2011; doi:10.1038/mp.2011.100.
Appleton KM, Rogers PJ, Ness AR . Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91: 757–770.
Martins JG . EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009; 28: 525–542.
Ross BM, Seguin J, Sieswerda LE . Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007; 6: 21.
Sublette ME, Ellis SP, Geant AL, Mann JJ . Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011; 72: 1577–1584.
Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008; 99: 421–431.
Bot M, Pouwer F, Assies J, Jansen EH, Diamant M, Snoek FJ et al. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord 2010; 126: 282–286.
Rondanelli M, Giacosa A, Opizzi A, Pelucchi C, La Vecchia C, Montorfano G et al. Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Am Coll Nutr 2010; 29: 55–64.
Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008; 42: 192–198.
Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009; 302: 1651–1657.
Lucas M, Asselin G, Merette C, Poulin MJ, Dodin S . Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 2009; 89: 641–651.
Freeman MP, Davis M, Sinha P, Wisner KL, Hibbeln JR, Gelenberg AJ . Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008; 110: 142–148.
Rees AM, Austin MP, Parker GB . Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 2008; 42: 199–205.
Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 644–651.
Grenyer BF, Crowe T, Meyer B, Owen AJ, Grigonis-Deane EM, Caputi P et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1393–1396.
Bax L, Yu LM, Ikeda N, Moons KG . A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med Res Methodol 2007; 7: 40.
Su KP, Huang SY, Chiu CC, Shen WW . Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13: 267–271.
Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006; 84: 1308–1316.
Lin PY, Su KP . A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68: 1056–1061.
Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 2009; 70: 1636–1644.
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R . Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252–260.
Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR . The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry 2011; 72: 1054–1062.
Peet M, Horrobin DF . A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913–919.
Nemets B, Stahl Z, Belmaker RH . Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477–479.
Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ . A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003; 160: 996–998.
Silvers KM, Woolley CC, Hamilton FC, Watts PM, Watson RA . Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 211–218.
da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008; 111: 351–359.
Rush JA, First MB, Blacker D . Handbook of Psychiatric Measures. 2nd edn. American Psychiatric Publishing, Inc.: Washington, 2008.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JGM provides research consultancy to the Academy of Nutritional Medicine, which is a not-for-profit organization that amongst its various activities oversees a clinic providing nutritional interventions for a variety of disorders, including depression. JGM has not participated in this clinic and has never prescribed nutritional interventions to patients. BKP is the author of a patent for a product comprising botanical triterpenes, ethyl-eicosapentaenoate and gamma-linolenic acid and received partial salary support as principal investigator of a phase III trial of ethyl-eicosapentaenoate in Huntington's chorea (Huntington disease) from Amarin Neuroscience Ltd. (formerly known as Laxdale Ltd.) published as Puri BK et al., Neurology 2005;65:286–292. HB declares no conflict of interest.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Martins, J., Bentsen, H. & Puri, B. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry 17, 1144–1149 (2012). https://doi.org/10.1038/mp.2012.25
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2012.25
This article is cited by
-
The role of polyunsaturated fatty acids in the neurobiology of major depressive disorder and suicide risk
Molecular Psychiatry (2024)
-
Recent trends in mental illness and omega-3 fatty acids
Journal of Neural Transmission (2020)
-
Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression
Neuropsychopharmacology (2018)
-
Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders
Journal of Inherited Metabolic Disease (2018)
-
Emulsified omega-3 fatty-acids modulate the symptoms of depressive disorder in children and adolescents: a pilot study
Child and Adolescent Psychiatry and Mental Health (2017)